IPO Alert · Subscription Period Mar 24–27, 2026
Sai Parenteral’s IPO:
₹409 Cr Issue. 72.19x P/E.
Is This Injection Worth The Jab?
A pharmaceutical company with four WHO-GMP facilities, a CDMO business on steroids, and a pre-IPO P/E that makes even Nifty 50 stalwarts look like bargains. Expanding capacity, eyeing global markets, and asking you to bet ₹14,896 minimum on syringes and tablets. Let’s check the vitals.
IPO Size₹409 Cr
Price Band₹372–₹392
Pre-IPO P/E72.19x
Market Cap (Post)₹2,140 Cr
Fresh Issue₹285 Cr
01 — At a Glance
The Needle Shop Wants Your Money. Badly.
- IPO Size (Total)₹408.79 Cr
- Fresh Issue₹285.00 Cr
- Offer for Sale₹123.79 Cr
- Lot Size (Min)38 shares
- Min Investment (Retail)₹14,896
- Book Running Lead ManagerArihant Capital
- RegistrarBigshare Services
- Listing DateApr 2, 2026
- TTM EPS (Sep 2025)₹5.43
- Pre-IPO NAV/Share₹35.98
Flash Summary: Sai Parenteral’s is a ₹409 crore IPO at 72.19x P/E. The company makes injectable drugs, has four WHO-GMP facilities, and is pivoting to CDMO services for the global market. Sep 2025 PAT was ₹7.76 crore on ₹89.43 crore revenue. Pre-IPO promoter stake: 61.23%. Post-IPO: they’ll dilute to 51.2%. The valuation is what we call “enthusiastic.” And yes, the IPO is already live. Day 1 subscription: 0.01x across all categories. Yes, you read that right — nearly nobody applied. This could be the shortest IPO party in market history.
02 — Introduction
Who Exactly Is Injecting What Into The Market?
Let’s rewind. Founded in 2001 by Anil Kumar Karusala, Vijitha Gorrepati, and Karusala Aruna, Sai Parenteral’s Ltd. is what the pharmaceutical world calls a “formulations company.” Translation: they don’t discover drugs. They manufacture them. And they make them really well — but almost nobody outside the industry knows they exist.
The company operates in two segments: Branded Generic Formulations (think Crocin, Amoxycillin, all those things your doctor prescribes) and Contract Development and Manufacturing Organisation services (CDMO — the sexy part where foreign pharma companies outsource production to Indians like they always have, except now Sai wants to charge them more for it).
They own five manufacturing facilities in India. Four in Hyderabad (including a WHO-GMP injectable unit, a TGA-Australia accredited unit, and a PIC/S accredited solid oral unit), and one in Ongole, Andhra Pradesh via subsidiary Revat Laboratories. In September 2025, they had 298 employees. In March 2025, they reported ₹14.43 crore in PAT. In September 2025, that dropped to ₹7.76 crore. If you know nothing about pharmaceutical cycles and margin compression, welcome — neither do most retail IPO applicants.
The Spin: They’re the “next big CDMO play.” The narrative is that Indian pharma companies are moving up the value chain, doing more complex work for global clients, earning better margins, and becoming the “contract manufacturers to the world.” All of that is true. Whether Sai Parenteral’s is the vehicle for your wealth creation? That’s the question. Currently, the market says “nope” — the IPO is subscribed just 0.01x on Day 1.
03 — Business Model: Making Pills So Others Don’t Have To
You Give Us A Formula. We Give You A Bottle. You Give Us Your Money. Simple.
Members get full access to every article.
